Re: ZEN-3694 in combination with "enzalutamide" in patients with metastatic castration resistant prostate cancer (mCRPC)
|
4
|
Zenith Epigenetics
|
Aug 27, 2021 06:18PM
|
Re: Another Exempt Distribution -2022-06-02
|
4
|
Resverlogix Corp.
|
Jun 05, 2022 01:12PM
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
4
|
Resverlogix Corp.
|
Dec 02, 2019 10:55AM
|
Re: Reading the tea leaves.....
|
4
|
Resverlogix Corp.
|
Jul 03, 2017 03:45PM
|
Re: Two articles - Apabetalone for Colon Cancer?
|
4
|
Resverlogix Corp.
|
Jul 09, 2021 10:50AM
|
Re: Interesting Uptick
|
4
|
Resverlogix Corp.
|
Apr 28, 2016 04:00PM
|
Re: Drop in price
|
4
|
Resverlogix Corp.
|
Jul 09, 2021 11:03AM
|
Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
4
|
Zenith Epigenetics
|
May 18, 2022 10:38AM
|
Re: RVX,,,,,,,,,,,,,,!
|
4
|
Resverlogix Corp.
|
Nov 23, 2015 11:24AM
|
Re: We Need An Update
|
4
|
Resverlogix Corp.
|
Jul 19, 2015 02:23PM
|
Re: European Atherosclerosis Society Congress May 29 - June 1
|
4
|
Resverlogix Corp.
|
May 27, 2016 05:00PM
|
Re: Wouldn’t the timing be great?
|
4
|
Zenith Epigenetics
|
Jun 18, 2019 12:36PM
|
Re: Naked short selling explained.....
|
4
|
Resverlogix Corp.
|
Jun 01, 2018 01:33PM
|
Votes In
|
4
|
Resverlogix Corp.
|
Jun 18, 2023 12:29PM
|
Re: Amarin CEO interview - New class action lawsuit
|
4
|
Resverlogix Corp.
|
Nov 14, 2018 04:31PM
|
Re: Biotech Showcase, Jan 13-15
|
4
|
Resverlogix Corp.
|
Jan 13, 2020 06:48PM
|
Re: Hoping we see something significant before June
|
4
|
Resverlogix Corp.
|
Feb 15, 2023 08:56AM
|
Re: Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment
|
4
|
Zenith Epigenetics
|
Jun 16, 2020 08:54AM
|
Re: Zenith AGM webcast 9/12/2018
|
4
|
Zenith Epigenetics
|
Sep 11, 2018 04:51PM
|
Re: early report imo
|
4
|
Resverlogix Corp.
|
Jul 03, 2022 12:09PM
|